P&T Committee

The Pharmacy and Therapeutics (P&T) Committee provides recommendations for the Medicaid Preferred Drug List (PDL). The Committee is composed of Physicians & Pharmacists who meet at least quarterly to consider PDL implementation. These meetings are generally scheduled on the third Thursday of every month at 7:15 A.M. in the Cannon Health Building at 288 N. 1460 W. in Salt Lake City, UT. The P&T Committee reserves the right to adjust the meeting schedule as necessary. Notices for exact meeting times and locations will be published in the Legal Notices sections of the Salt Lake Newspapers at least 24 hours in advance.

The meetings are open to the public. To receive public notice for this meeting by email please sign up on the Utah Public Notice website.

Public Comments for the P&T Committee:

Public comment that responds to the materials presented by the Pharmacotherapy Outcomes Research Center at the Universityof Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting.

Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:

Gary M. Oderda, Pharm.D., M.P.H
Professor and Director
Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
30 South 2000 East Room 4922
Salt Lake City, UT 84112

All materials must be clearly labeled that they are submitted for consideration as part of the State of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Persons who wish to address the P&T Committee may contact Utah Medicaid by email, at medicaidpharmacy@utah.gov at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints

Listed below is a P&T Committee class review tentative schedule:

P&T Tentative Schedule:

  • June 2016: 2nd Generation Anticonvulsants
  • July 2016: SSRIs/SNRIs (and similar)
  • August 2016: Other Antidepressants/Serotonergic Agents
  • September 2016: Tricyclic Antidepressants (TCAs)
  • October 2016: 1st Generation Anticonvulsants
  • November 2016: Anti-Anxiety Agents
  • December 2016: No Meeting
  • January 2017: Targeted Immune Modulators
  • February 2017: HIV - Non-Nucleoside Reverse Transcriptase Inhibitors and HIV - Nucleoside Reverse Transcriptase Inhibitors
  • March 2017: HIV – Integrase Inhibitors and HIV - Fusion Inhibitors
  • April 2017: Antineoplastic Antibiotics
  • May 2017: Antimetabolite Agents (Antifolate agents, Purine analogs, Pyrimidine analogs)
  • June 2017: Monoclonal Antibodies (Antineoplastic)
  • July 2017: DNA Demethylation Agents and DNA Topoisomerase Inhibitors
  • August 2017: Histone Deacetylase Inhibitors and Platinum Coordination Complex

Please note that the topics listed above are tentative and subject to change.

Listed below are meeting minutes, recordings, agendas, criteria review documents, and reports regarding the P&T Committee. Clinical evidence documents prepared for the P&T Committee meetings will be kept on this website for 6 months.

Meeting recordings will be available online for 1 year. For historical meeting recordings please contact us at medicaidpharmacy@utah.gov.

Current Criteria Review Documents available include:

  • March 2015: Thiazide Diuretic Agents AND Loop Diuretics AND Potassium-Sparing Diuretics
  • April 2015: Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors
  • May 2015: Antianginal Agents
  • June 2015: No Meeting
  • July 2015: Hepatitis C Combination Agents
  • August 2015: HIV Protease Inhibitors
  • September 2015: Bowel Cleansing Agents AND Agents Indicated in the Treatment of Irritable Bowel Syndrome
  • October 2015: Immune Globulin Agents
  • November 2015: Ophthalmic Beta-Blockers AND Ophthalmic Cholinergic Agonists
  • December 2015: Agents for Opioid Induced Constipation
  • January 2016: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
  • February 2016: Skeletal Muscle Relaxants
  • March 2016: Long Acting Opioids

The documents are provided as Portable Document Format (PDF) files. If you cannot view a file, please download the free reader from the link below.

Get Adobe Acrobat Reader